Claudin 4 Protein-VLP (CLDN4) (AA 1-209)

Catalog No. ABIN7504302

This VLP Claudin 4 protein is produced in HEK-293 Cells.

Quick Overview for Claudin 4 Protein-VLP (CLDN4) (AA 1-209) (ABIN7504302)

Target: Claudin 4 (CLDN4)

Protein Type: VLP

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purity: > 95 % as determined by HPLC

Product Details

Protein Characteristics: AA 1-209

Purpose: Human Claudin 4 VLP

Sequence: Met1-Val209

Characteristics: Recombinant Human Claudin 4 VLP is expressed from HEK293.It contains Met1-Val209 (It may have cross reaction with anti-His antibody).

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1 EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human Claudin 4 VLP at 5ug/ml (100ul/well) on the plate. Dose response curve for Anti-Claudin 4 Antibody, hFc Tag with the EC50 of 6.5ng/ml determined by ELISA (QC Test).,The purity of Human Claudin 4 VLP is greater than 95% as determined by SEC-HPLC.

Application Details

Comment:

Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Supplied as 0.22μm filtered solution in PBS, 300 mM L-arginine ( pH 7.4). Notice: If you need it for immunization, water-soluble adjuvant is recommended.

Storage: -80 °C

Storage Comment: Valid for 12 months from date of receipt when stored at -80°C.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: Claudin 4 (CLDN4)

Alternative Name: Claudin 4

Background: Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors.

Molecular Weight: 23.31 kDa.

UniProt: O14493

Pathways: Hepatitis C